Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 9
Submit an article Journal homepage
639
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia

Jill Fulchera Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0369-5034
ORCID Icon,
Philip Berardib Department of Pathology and Laboratory Medicine, University of Ottawa and Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Canada
,
Grace Christoua Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Canada
,
Pierre J. A. Villeneuvea Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Canada
,
Christopher Bredeson
&
Mitchell Sabloffa Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, CanadaORCID Iconhttps://orcid.org/0000-0002-0122-6138
ORCID Icon
Pages 2295-2297 | Received 14 Jan 2021, Accepted 27 Feb 2021, Published online: 21 Mar 2021

References

  • Patel AA, Thomas J, Rojek AE, et al. Biology and treatment paradigms in t cell acute lymphoblastic leukemia in older adolescents and adults. Curr Treat Options Oncol. 2020;21(7):57.
  • Castaneda Puglianini O, Papadantonakis N. Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts. Ther Adv Hematol. 2020;11:2040620720929475.
  • O’Dwyer KM. T-cell lymphoblastic leukemia: what are the prospects for novel immunotherapy? Hematol. 2020;17(3). https://doi.org/10.1182/hem.V17.3.10366.
  • Bonda A, Punatar S, Gokarn A, et al. Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia – a worthwhile strategy? Bone Marrow Transplant. 2018;53(11):1487–1489.
  • Commander LA, Seif AE, Insogna IG, et al. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol. 2010;150(3):345–351.
  • Dunsmore KP, Winter SS, Devidas M, et al. Children's oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020;38(28):3282–3293.
  • DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801. Blood. 2007;109(12):5136–5142.
  • Gökbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118(13):3504–3511.
  • Bride KL, Vincent TL, Im S-Y, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131(9):995–999.
  • van de Donk NWCJ, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270(1):95–112.
  • Wynne J, Stock W. "Dar"-ing to target CD38 in T-ALL. Blood. 2018;131(9):948–949.
  • Mirgh S, Ahmed R, Agrawal N, et al. Will daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia? Br J Haematol. 2019;187(2):e33–e35.
  • Ofran Y, Ringelstein-Harlev S, Slouzkey I, et al. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia. Leukemia. 2020;34(1):293–295.
  • Cerrano M, Castella B, Lia G, et al. Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2020;191(1):e28–e32.
  • Tout M, Casasnovas O, Meignan M, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood. 2017;129(19):2616–2623.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.